1 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
βGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
9PubMed Papers
5Diseases
0Drugs
0Pathogenic Variants
DATA QUALITYβ Experimental GO Evidenceβ Swiss-Prot Reviewed
protein bindingbeta-galactoside (CMP) alpha-2,3-sialyltransferase activityglycoprotein biosynthetic processsialylationresponse to statindrug allergyAbnormality of the skeletal systememphysema
Based on limited published evidence, C20orf173 is an uncharacterized protein with predicted roles in glycoprotein biosynthesis and sialylation. GO annotations indicate protein binding capacity and beta-galactoside alpha-2,3-sialyltransferase activity, suggesting involvement in cell surface glycan modification and membrane-associated processes. A recent proteomic discovery study identified C20orf173 as a novel protein associated with pulmonary emphysema in a population-based cohort, with associations replicated in COPD studies 1. The protein was retained in predictive models and contributed to explaining emphysema variance, though its specific mechanistic role remains undefined.
1
C20orf173 identified as novel protein significantly associated with percent emphysema in MESA Lung Study, with replication in SPIROMICS and COPDGene studies; retained in LASSO models and contributed unique explanatory variance
PMID: 40616090β Limited data available β This gene has 1 indexed publication. Summary and analysis may be incomplete.
response to statinOpen Targets
Abnormality of the skeletal systemOpen Targets
esophageal cancerOpen Targets
No pathogenic variants reported on ClinVar for this gene.